CA-CEPTON-TECHNOLOGIES
16.3.2021 13:02:10 CET | Business Wire | Press release
Cepton, a leading provider of intelligent, lidar-based solutions, today announced a partnership with top perimeter security solutions provider, Barrier1 Systems. Using Cepton’s Helius™ Smart Lidar System , Barrier1 Systems is adding new layers of intelligence to its physical barrier systems to enable the next-generation of early-warning intrusion detection and onsite safety applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005303/en/
North Carolina-based Barrier1 Systems is working with global customers in the public and private sectors to install innovative new solutions that leverage the unique capabilities of Cepton ’s Helius system, which combines a network of Vista®-P lidar sensors with edge computing and advanced perception software, to deliver real-time, anonymized, 3D object detection, classification, tracking and velocity. The partnership demonstrates the versatility of Cepton’s lidar technology, and how smart lidar solutions are increasing security and safety in various types of public and private commercial spaces and facilities.
In one customer application, Barrier1 Systems has combined its barrier control systems with Helius to monitor the speed and direction of vehicles approaching entrance or exit points. If a vehicle exceeds a certain speed limit within a specified range, the system will flag it as a potential intrusion attempt and trigger an alert to the central system for further actions. By classifying vehicle travel direction, it can also guard against incoming threats through outbound roadways.
Deployments like the one above utilize the Cepton Vista lidar’s long range, high resolution imaging capabilities, and the Helius solution’s real-time, 3D information on object dimensions, locations and velocities. For example, Barrier 1 Systems uses Helius to detect and classify vehicles at 150 meters and keep track of their velocities to help diagnose whether there is a potential breach. The object information from Helius is much more accurate than from radars, thereby minimizing false positives and false negatives.
Barrier1 Systems has also deployed Cepton’s Helius system to help ensure facility security and onsite safety. For instance, a network of Vista-P90 lidar sensors has been installed at customer inventory sites to monitor access points. Helius generates useful information such as whether a detected object is a vehicle or a person, how fast it is moving and whether it is in a pre-defined exclusion zone. As lidars perform 24/7 under many weather and lighting conditions challenging for cameras, this helps facility managers continuously ensure property security and worker safety. Facilities can utilize the smart lidar data to flag potential accidents and breaches of access control.
Speaking of the partnership, Baxter Matthews, Vice President of Security Projects at Barrier1 Systems, said: “Cepton’s lidar technology and perception solution have allowed us to unleash a new set of innovations and capabilities when it comes to security and safety, which is critical given the range of threats and challenges faced today in both public and private spaces. The simplicity of installation of Cepton’s solution makes it easy for us to deploy and scale up quickly. Further, the anonymous nature of the lidar images, combined with their high accuracy, enables significant advancements in the state of the art for security and safety. A major customer liked the advantages of our solution so much that they want to do a nationwide implementation at all of their sites, which is incredible. What’s exciting is that we are just scratching the surface of what is possible because there are many untapped applications – in the perimeter security industry and beyond – where customers see tremendous potential for solutions arising from our partnership with Cepton.”
Dr. Jun Pei, Cepton’s co-founder and CEO, added: “Beyond its well-known role in the automotive industry, lidar is a versatile technology that enables a whole new level of safety and autonomy in many other applications. Our partnership with Barrier1 is a testament to this. We have designed our MMT®-based lidar solutions with customers’ perception needs in mind, and for security and safety solutions like the ones developed by Barrier1, we have focused on delivering a superior combination of accuracy, reliability and scalability. We look forward to continuing our work with Barrier1 to expand the use cases for lidar globally, by enabling enhanced safety and security solutions using lidar intelligence.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About Barrier1
Barrier1 Systems, LLC (Barrier1 Systems) provides state-of-the-art robust physical barriers and security solutions using innovative products with unique capabilities that meet the customer’s site-specific needs and requirements. In the past 17 years, more than 4500 of our crash rated barrier systems have been fielded in 13 countries.
Barrier1 Systems employs expertise in engineering, welding and metal works, controls & alarms, electronics, power systems, programming, manufacturing, and installation. The company was founded in 2002. Barrier1 Systems does engineering and direct manufacturing for its products and provides post-installation support. For more information about Barrier1 visit www.barrier1.us .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
